T wo aspects of hypertension that have received considerable attention in recent years are the threshold blood pressure (BP) for diagnosing hypertension and the optimum BP target after drug therapy has been initiated. In each instance, greater emphasis is now given to systolic BP, primarily because it has been shown in numerous studies to be the best predictor of cardiovascular risk. Thresholds for the initiation of therapy based on increases in future cardiovascular events in relation to BP have been determined 1-3 for 24-hour ambulatory BP monitoring, home BP, and electronic, automated office BP (AOBP). As for conventional manual office BP, treatment thresholds were mainly derived from placebo-controlled clinical trials. For example, in the SHEP trial (Systolic Hypertension in the Elderly Program), 4 hypertension was defined as a systolic BP of 160 mm Hg or higher, and the target BP was a decrease of at least 20 mm Hg to <150 mm Hg. This study provided evidence to support treating isolated systolic hypertension of 160 mm Hg or higher in the elderly. Clinical outcome data that would justify treating uncomplicated, mild diastolic hypertension (90-99 mm Hg) based on placebo-controlled clinical trials are lacking. Other epidemiological studies 5 have shown an increase in cardiovascular events in mixed treated and untreated populations starting at a BP ≥115/75 mm Hg. However, these findings only relate BP to the future risk of a cardiovascular event and do not address the optimum BP after drug therapy has been started. Overall, convincing evidence for initiating drug therapy for uncomplicated, mild hypertension (BP 140-159/90-99 mm Hg) based on office BP is limited.
T wo aspects of hypertension that have received considerable attention in recent years are the threshold blood pressure (BP) for diagnosing hypertension and the optimum BP target after drug therapy has been initiated. In each instance, greater emphasis is now given to systolic BP, primarily because it has been shown in numerous studies to be the best predictor of cardiovascular risk. Thresholds for the initiation of therapy based on increases in future cardiovascular events in relation to BP have been determined [1] [2] [3] for 24-hour ambulatory BP monitoring, home BP, and electronic, automated office BP (AOBP). As for conventional manual office BP, treatment thresholds were mainly derived from placebo-controlled clinical trials. For example, in the SHEP trial (Systolic Hypertension in the Elderly Program), 4 hypertension was defined as a systolic BP of 160 mm Hg or higher, and the target BP was a decrease of at least 20 mm Hg to <150 mm Hg. This study provided evidence to support treating isolated systolic hypertension of 160 mm Hg or higher in the elderly. Clinical outcome data that would justify treating uncomplicated, mild diastolic hypertension (90-99 mm Hg) based on placebo-controlled clinical trials are lacking. Other epidemiological studies 5 have shown an increase in cardiovascular events in mixed treated and untreated populations starting at a BP ≥115/75 mm Hg. However, these findings only relate BP to the future risk of a cardiovascular event and do not address the optimum BP after drug therapy has been started. Overall, convincing evidence for initiating drug therapy for uncomplicated, mild hypertension (BP 140-159/90-99 mm Hg) based on office BP is limited.
There has also not been a specific target BP for treating systolic hypertension, with some guidelines recommending a <150 mm Hg target in the elderly based on the results of the SHEP trial, whereas others have maintained the Abstract-The SPRINT (Systolic Blood Pressure Intervention Trial) reported that some older, higher risk patients might benefit from a target systolic blood pressure (BP) of <120 versus <140 mm Hg. However, it is not yet known how the BP target and measurement methods used in SPRINT relate to cardiovascular outcomes in real-world practice. SPRINT used the automated office BP technique, which requires the patient to be resting quietly and alone, with multiple readings being recorded automatically using an electronic oscillometric sphygmomanometer. We studied the relationship between achieved automated office BP at baseline and cardiovascular events in 6183 community-dwelling residents of Ontario aged ≥66 years who were receiving antihypertensive therapy and followed for a mean of 4.6 years. Adjusted hazard ratios (95% confidence intervals) were computed for 10 mm Hg increments in achieved automated office BP at baseline using Cox proportional hazards regression and the BP category with the lowest event rate as the reference category. historical cut point of <140 mm Hg. 6 Two studies, the HOT study (Hypertension Optimal Therapy) 7 and the ACCORD study (Action to Control Cardiovascular Risk in Diabetes), 8 have examined treatment targets in hypertensive patients with diabetes mellitus. In the HOT trial, diastolic BP targets of <90, <85, and <80 mm Hg were compared for a reduction in cardiovascular outcome rates. Overall, there was no evidence of a significantly greater benefit for lower versus higher target diastolic BP values, despite enrollment of almost 19 000 patients. However, in a subgroup with diabetes mellitus, there was a 51% reduction in major CV events in the target diastolic group of <80 mm Hg compared with the target group <90 mm Hg. In contrast, in the ACCORD trial, patients with hypertension and diabetes mellitus did not show clinically or statistically significant differences in the primary end point, major adverse cardiac events, when the target systolic BP was <140 versus <120 mm Hg. It should be noted that the ACCORD trial is somewhat underpowered in that it enrolled about half the number of subjects as in SPRINT (Systolic Blood Pressure Intervention Trial).
The SPRINT is similar to the ACCORD study, except that it enrolled a nondiabetic cohort of older hypertensive patients with relatively high cardiovascular risk. 9 In SPRINT, treating hypertension to a lower target systolic BP of <120 mm Hg resulted in fewer cardiovascular events than treating to the current target of <140 mm Hg. The results of SPRINT are likely to influence the target BP recommended in hypertension guidelines. What is not immediately apparent is the impact of how BP was measured in SPRINT and its consequences for clinical practice. In SPRINT, BP was recorded using the Omron 907XL electronic sphygmomanometer 10, 11 in accordance with the procedures for AOBP measurement-multiple BP readings recorded automatically with the patient resting quietly and alone. AOBP provides more accurate BP readings than conventional manual BP and virtually eliminates a white coat effect. Unlike office BP recorded by medical staff, mean AOBP is similar to the awake ambulatory BP and home BP, with all 3 techniques having the same cut point for defining hypertension (135/85 mm Hg). In the present study, we sought to complement the findings of SPRINT by following 6183 community-dwelling individuals for whom we had data on both AOBP and drug therapy to explore the relationship between achieved BP measured with AOBP at baseline and subsequent cardiovascular events in routine clinical practice.
Methods
The study population was obtained from patients enrolled in the CHAP (Cardiovascular Health Awareness Program) who were receiving antihypertensive drug therapy at baseline. 12 CHAP was a cluster randomized trial involving 39 medium-sized Ontario communities with the aim of demonstrating that a multifactorial community-based BP awareness program could reduce hospitalization caused by cardiovascular events. Details of the CHAP trial have been published previously.
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Study Subjects
Community-dwelling residents who were aged ≥66 years were eligible for enrollment in the present study if they attended at least one AOBP session in CHAP and were receiving antihypertensive drug therapy at the time BP was measured. Exclusion criteria included missing personal identifiers, which prevented linkage of their AOBP reading with Ontario administrative health data, less than a 365-day history of prescription drug claims (which excluded persons <66 years of age), enrollment in the OHIP (Ontario Health Insurance Program) for <3 years, and absence of an AOBP reading at baseline.
Procedures
Residents of CHAP intervention communities had their BP recorded in participating pharmacies according to a standard AOBP protocol 14 using a BpTRU device (BpTRU Medical Devices Inc, Coquitlam, BC, Canada). Subjects visited the pharmacies at various times during the day, with the majority of sessions held between 0900 and 1200 hours. BP readings were obtained under the supervision of volunteer lay persons who were trained by nurses and pharmacists on the proper recording of AOBP according to the guidelines 15 of the CHEP (Canadian Hypertension Education Program). The CHEP protocol for recording AOBP required that participants rest seated in a quiet place, undisturbed, before and during the readings. The research staff remained nearby but did not speak to the subjects or otherwise interact with them. The standard 5 minutes of rest before manual BP is not part of the AOBP protocol. AOBP recorded in this setting and using the identical procedures has been shown to be equivalent to AOBP readings obtained in the family physician's office. 16 The fully automated BpTRU recorder was set to take 5 readings at 1-minute intervals, with the patient resting quietly undisturbed after an initial test reading, which verified that the device was functioning properly. The BpTRU device then automatically computed the mean of the 5 AOBP readings. Study personnel informed the patient and the patient's own family physician of the BP reading, but any subsequent actions, such as changes in antihypertensive drug therapy, were left to the physician.
Data Collection and Cardiovascular Outcomes
The baseline characteristics of participants were obtained via a selfadministered questionnaire (for cardiovascular risk factors) and routinely collected administrative health-care records. The Ontario Drug Benefit Program provided information on claims for prescription medicines before enrollment and during follow-up periods. Detailed diagnostic and procedure information on participants, including hospitalizations, was available from the Canadian Institute for Health Information Discharge Abstract Database. The OHIP Claims History Database was used to identify claims for both outpatient and inpatient visits to physicians. Validated administrative data case definitions were used to identify relevant comorbidities, including hypertension, congestive heart failure, diabetes mellitus, and end-stage renal disease, as previously described. 3 Subjects were followed from the date of their baseline AOBP measurement, which was conducted between September and November 2006, to the first of a nonfatal cardiovascular event (to March 31, 2013), cardiovascular death (to December 31, 2011, because of a 2-year lag period in the availability of cause-specific mortality data), loss of OHIP coverage, or the end of the study period. The primary outcome measure was a composite of acute care hospitalization with a most responsible (primary) discharge diagnosis of acute myocardial infarction, congestive heart failure or stroke, or mortality in which cardiovascular disease was the primary cause of death. The Canadian Institute for Health Information's Discharge Abstract Database was used to capture hospitalizations with validated ICD-10-CA (International Classification of Diseases, 10th revision, Canadian Enhancement) diagnosis codes having high positive predictive values. Deaths because of a cardiovascular cause, as recorded on provincial death certificates, were identified in the Ontario Registrar General Death Register.
Statistical Analysis
The baseline characteristics of participants were summarized using descriptive statistics. Cardiovascular event rates expressed per person-year of follow-up were computed (with 95% confidence limits) and tabulated according to 10 mm Hg categories of achieved mean systolic and diastolic AOBP values at baseline and to pulse pressure (systolic minus diastolic AOBP). Hazard ratios (HR) adjusted for relevant covariables with 95% confidence intervals were computed for each 10 mm Hg increment in AOBP using Cox proportional hazards regression, with the BP category having the lowest event rate set as the reference category. All analyses were performed on anonymized, encoded records at the Institute for Clinical Evaluative Sciences (www.ices.on.ca) using SAS Enterprise Guide version 6.1 (SAS Institute, Cary, NC) and a 2-tailed type 1 error rate of 0.05 as the threshold for statistical significance.
Results
A total of 15 889 individuals attended at least one CHAP session and had their AOBP and self-reported risk factor data recorded. Of these, 13 449 provided informed consent and personal identifiers with which to link their characteristics and AOBP with Ontario administrative health data. Among these individuals, 2601 (19%) were aged <66 years, 974 (7%) had missing risk factor data, 63 (0.5%) had less than the minimum 3 years of prior Ontario Health Insurance Program coverage, and 3628 (27%) had no prescription drug claims for antihypertensive therapy in the 120 days preceding BP measurement. The remaining 6183 subjects formed the evaluable cohort for the present study.
Demographic and clinical characteristics of study participants are presented in Table 1 . Their mean±SD age was 76.2±6.1 years. Forty-two percent were males, 5.7% were self-reported smokers, and 48.1% self-reported having high blood cholesterol. Twenty-seven percent had diabetes mellitus, 11.9% had congestive heart failure, and 91.9% had a prior diagnosis of hypertension. Mean AOBP was 134.3±20.3/72.9±11.0 mm Hg.
Differences in antihypertensive drug therapy between baseline and the end of follow-up are shown in Table 2 . The mean period of follow-up was 4.6±1.3 years. The number of patients who had at least one drug added was similar to the number who either had one drug stopped or who stopped antihypertensive drug therapy altogether. The mean number of antihypertensive drugs at baseline for each AOBP category varied between 1.8±0.8 and 1.9±0.9.
Cardiovascular Outcomes in Relation to Blood Pressure
There were 904 nonfatal and fatal cardiovascular events during follow-up. The crude event rates per 1000 person-years for each 10 mm Hg category of systolic BP, diastolic BP, and pulse pressure at baseline are shown in Table 3 . The crude event rate for systolic BP was relatively stable between 120 to 129 and 140 to 149 mm Hg categories, being lowest in the range of 110 to 119 mm Hg. For diastolic BP, the crude event rate was relatively stable >60 mm Hg, being slightly lower at 80 to 89 mm Hg. There were too few events in persons with a diastolic BP ≥100 mm Hg to examine the cardiovascular risk associated with BP readings in this range. There was a marked increase in the event rate in the <60 mm Hg category.
The relationship between categories of AOBP and the composite primary outcome was examined further after adjustment for relevant covariables (Table 4 ). There was a decrease in the adjusted HR down to a systolic BP <150 mm Hg (Figure) . The HR values remained relatively unchanged between 120 and 149 mm Hg, with no significant changes noted within these categories. Thereafter, the HR reached a nadir at 110 to 119 mm Hg, with the lower confidence interval for the category of 120 to 129 mm Hg being greater than unity.
The AOBP category with the lowest adjusted HR for the composite primary outcome was the same (systolic BP 110-119 mm Hg) for the 1673 subjects with a diagnosis of diabetes mellitus and the 4510 nondiabetic subjects.
For diastolic BP, the HR values for categories >70 mm Hg were relatively similar, with the only significant increase in HR occurring in the category of <60 mm Hg (Table 4 ; Figure  S1 in the online-only Data Supplement). There were too few events in people with a diastolic BP ≥100 mm Hg to examine the cardiovascular risk associated with BP readings in this range. The HR in the pulse pressure categories were similar ≤70 to 79 mm Hg, with a significant increase in HR seen at Figure S2 ). Data for noncardiovascular death are shown in Table S1 . For systolic BP, the mean ages for the BP categories varied between 75.8 and 77.4 years (Table S2 ). There were more females (63.1%) in the highest (160+ mm Hg) BP category and more males (51.1%) in the lowest (<110 mm Hg) BP category. For diastolic BP, there was a progressive decrease in mean age and progressive increase in the percent of males from lowest to highest BP category.
Discussion
In the present study, subjects aged ≥66 years living in the community who had their BP measured using the AOBP technique as part of the CHAP study protocol were followed for the development of a fatal or nonfatal cardiovascular event using administrative data. Unlike a clinical trial such as SPRINT, 9 these individuals were subject to usual medical care after baseline AOBP measurements were obtained, including subsequent treatment of their hypertension based on conventional manual BP measurement. As a randomized controlled clinical trial, SPRINT provides strong evidence for a target systolic AOBP <120 mm Hg in older, higher risk hypertensive patients. Nonetheless, there is already a debate developing on how to translate the more accurate but lower AOBP readings in SPRINT into routine clinical practice. 11 In such circumstances, real-world data on clinical cardiovascular outcomes in relation to achieved AOBP on antihypertensive therapy should be especially useful. Of interest, the intensity of drug therapy for hypertension at baseline was similar in both SPRINT and in our cohort (mean 1.8 antihypertensive drugs per day), both representing treated hypertension in usual clinical practice in Canada and the United States.
As in SPRINT, the incidence of cardiovascular events in our study was lowest when the achieved systolic BP recorded at baseline was lower, 110 to 119 mm Hg in our cohort. Subjects with systolic BP readings in the range of 120 to 149 mm Hg had HR values that were only slightly higher (1.18-1.30), which might explain why somewhat smaller studies with less power were not able to detect a statistically significant difference between a lower versus higher target BP on treatment. Subjects enrolled in SPRINT differed somewhat from the participants in our study; for SPRINT versus our cohort: age 68 versus 76 years, mean AOBP at baseline 140/78 versus 134/73 mm Hg, nonsmokers 86% versus 94%, body mass index 30 versus 27, untreated hypertension 9.4% versus 0%. Individuals with diabetes mellitus and prior stroke were excluded from SPRINT, whereas 27.1% and 2.5% of the subjects in our study, respectively, had diabetes mellitus or prior stroke. The duration of follow-up was a median of 3.3 years in SPRINT and a median of 5.2 years in our study. The subjects enrolled in SPRINT underwent a rigorous assessment of their BP status, including a careful evaluation of their antihypertensive therapy and repeat AOBP measurements in those with only mild hypertension. In contrast, our subjects were residents in the community who were participating in a BP screening program. Their subsequent antihypertensive therapy after the baseline AOBP readings were obtained was managed in routine clinical practice and not as part of a rigorous study protocol, as was done in SPRINT.
The findings in our older cohort support systolic BP and pulse pressure as the parameters of interest in evaluating cardiovascular risks associated with BP. There was a significantly higher HR at pulse pressures of 80 mm Hg and higher, whereas increasing diastolic BP failed to show any gradient in cardiovascular risk. These observations are consistent with an increased arterial stiffness in older people.
Although AOBP in our study was recorded in a pharmacy setting, studies [16] [17] [18] have shown that AOBP readings are independent of the location in which they are taken, provided that the principles of AOBP are followed: multiple readings recorded automatically with the patient resting undisturbed in a quiet place. Of direct relevance to the present study, AOBP readings performed in community pharmacies using the CHAP protocol should be similar to the AOBP readings taken in the offices of the patients' own family physicians. 16 Other studies have shown that different devices for recording AOBP, such as the Omron 907XL in SPRINT and the BpTRU in our study, produce similar results. 19 Our approach to analyzing the AOBP data is derived from several different hypertension studies, including a previous study in participants in CHAP who were untreated for hypertension. 3 Bangalore et al 20 examined the continuous relationship between cardiovascular risk expressed as HR and BP and reported the lowest point of risk in their population (95% hypertensive) with associated abnormal serum lipids. Sundstrom et al 21 performed a similar analysis in over 34 000 primary care patients with a wide range of BP values (40% hypertensive). However, these authors also divided their subjects into 5 risk categories to examine the relationship between BP and HR. Other studies have used similar designs in a variety of populations, including normotensive subjects, to assess cardiovascular risk related to BP over a wide BP range. [22] [23] [24] Each study has unique features pertaining to special aspects of their population and BP data.
When it comes to relating BP to cardiovascular risk, only SPRINT and our study used AOBP. AOBP is more accurate than conventional manual BP and is even ≈5/5 mm Hg lower than the BP readings recorded in a research study 25 according to standard guidelines, even if an electronic sphygmomanometer is used. 26 In the recently published Secondary Prevention of Small Cortical Strokes Trial, 27 which randomized patients to a lower versus higher target BP for treating their hypertension, the optimal mean BP on treatment recorded with an electronic device was 124/67 mm Hg. Subtracting 5/5 mm Hg from this value would give a target consistent with the results of both SPRINT and our study. As with all types of office BP measurement, AOBP alone cannot detect which patients with a normal office reading actually have masked hypertension, with hypertension based on ambulatory BP monitoring or home BP. However, in one study, 28 AOBP was associated with a significantly lower rate of masked hypertension compared with routine manual office BP readings.
When it comes to extrapolating the findings of SPRINT and our study to clinical practice, it should be noted that AOBP readings are on average ≈15/8 mm Hg lower than usual BP as measured in real-life settings such as in doctors' offices in the community. 12 This mean value represents subjects with a wide range of white coat effect, so that it is not possible to use a simple correction factor to translate routine BP readings into AOBP. This feature could explain why the subjects in different categories of AOBP in our study were receiving the same mean number of antihypertensive drugs. Treatment in these individuals was based on routine manual BP readings, so that the 20% to 25% individuals with a greater white coat effect would tend to get more antihypertensive therapy, independent of their AOBP category. The one conclusion from our results that is most certain is that treating hypertension to the lower threshold in SPRINT is unlikely to cause harm, provided that AOBP measurements are used. The safety of the <120 mm Hg target in SPRINT is even more certain if one takes into account that, unlike in our analysis based on achieved BP at baseline, only about one half of the lower target subjects achieved a systolic AOBP <120 mm Hg.
Aside from the collection of AOBP data, this study was conducted in a real-world setting, which is both its major strength and weakness. This type of research is much different than a randomized controlled trial, such as SPRINT. The population consisted of older residents in the community and not a sample of patients selected according to specific inclusion and exclusion criteria. This feature reduces internal validity but enhances external validity and, thus, the relevance of the findings to usual clinical practice. The pretreatment BP and reasons for initiating antihypertensive therapy in our cohort are unknown. However, each individual's hypertension before and after enrollment was managed in the community, with the baseline AOBP reading representing their status at one point in time. Many of these older subjects would have had a white coat effect, and these individuals were possibly overtreated, whereas others may have been left with mild hypertension because of therapeutic inertia. The AOBP readings likely reflected these aspects of routine practice. Also, AOBP was not recorded at a specific time in the day, and we do not know the duration of hypertension in each subject. We also do not have sufficient information with which to calculate lifetime BP load. Overall, the rigor of our study's design and management of hypertension, given its pragmatic nature, is different from that of a high-quality clinical trial. Nonetheless, its findings are more representative of usual clinical practice and demonstrate that AOBP is a useful predictor of cardiovascular risk, despite patient management not being dictated by a research protocol.
Conclusions
There is now more reason than ever to abandon manual BP measurement, which is less accurate than AOBP and associated with a white coat effect, potentially resulting in misdiagnosis of hypertension in clinical practice. SPRINT has demonstrated that treating older patients with a higher cardiovascular risk based on AOBP to a lower threshold systolic BP <120 mm Hg significantly reduces cardiovascular end points. 9 The Canadian hypertension guidelines recommend AOBP as the preferred method for office BP measurement and have now reduced target systolic AOBP to <120 mm Hg in older, higher risk hypertensive patients based on the findings in SPRINT. 29 The results of the present study obtained in clinical practice support the findings in SPRINT. It is now time to use AOBP in routine clinical practice.
Perspectives
The present study extends the findings of SPRINT to a realworld setting by confirming that a systolic AOBP in the range of 110 to 119 mm Hg is associated with the lowest rate of cardiovascular events. Not only do these results support the target BP in SPRINT, they also question the viability of current methods used to measure BP in the office. Both SPRINT and our study used AOBP, which produces more accurate and lower (by ≈15/8 mm Hg) readings than conventional manual office BP. If the findings in SPRINT lead to lower BP targets for treatment, then the method of BP measurement will also need to be reassessed. The evidence supporting the routine use of AOBP in clinical practice has already led to some guidelines recommending AOBP as the preferred method for office BP measurement. SPRINT is now destined to have an impact on the target BP for antihypertensive drug therapy, with Canadian guidelines 29 having recently adjusted its target systolic AOBP for older, higher risk patients to <120 mm Hg. Because AOBP, daytime ambulatory BP monitoring, and home BP all use the same threshold for diagnosing hypertension, <135/85 mm Hg, there would seem to be little reason to cling to 19th century technology for recording BP when electronic methods are superior for both the diagnosis of hypertension and managing patients on antihypertensive drug therapy.
Sources of Funding
This study was supported by a grant from the Canadian Institutes of Health Research and by the Institute for Clinical Evaluative Sciences, a nonprofit research institute funded by the Ontario Ministry of Health and Long-Term Care. The study's sponsors had no role in designing the study; collecting, analyzing, or interpreting the data; writing the report; or in the decision to submit the article for publication. The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by the Institute for Clinical Evaluative Sciences or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred.
Disclosures
None. Figure S1 . Adjusted hazard ratios (and 95% confidence intervals) for cardiovascular events according to category of diastolic blood pressure. Figure S2 . Adjusted hazard ratios (and 95% confidence intervals) for cardiovascular events according to category of pulse pressure.
